Pharmacogenomics in the era of next generation sequencing – from byte to bedside

References

• Achour B, Al‐Majdoub ZM, Grybos‐Gajniak A, Lea K, Kilford P, Zhang M, Knight D, Barber J, Schageman J, Rostami‐Hodjegan A. 2021. Liquid biopsy enables quantification of the abundance and interindividual variability of hepatic enzymes and transporters. Clin Pharmacol Ther. 109(1):222–232.
   PubMed Web of Science ®Google Scholar
• Adams SM, Anderson KB, Coons JC, Smith RB, Meyer SM, Parker LS, Empey PE. 2016. Advancing pharmacogenomics education in the core PharmD curriculum through student personal genomic testing. Am J Pharm Educ. 80(1):3.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Day CP, Kesteven PJ, Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet. 353(9154):717–719.
   PubMed Web of Science ®Google Scholar
• Almeida AM, Ramos F. 2016. Acute myeloid leukemia in the older adults. Leuk Res Rep. 6:1–7.
   PubMedGoogle Scholar
• Ammar R, Paton TA, Torti D, Shlien A, Bader GD. 2015. Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. F1000Res. 4:17.
   PubMedGoogle Scholar
• Bank PCD, Swen JJ, Schaap RD, Klootwijk DB, Baak-Pablo R, Guchelaar H-J. 2019. A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care. Eur J Hum Genet. 27(10):1532–1541.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. 2010. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 12(2):R63.
   PubMed Web of Science ®Google Scholar
• Bethune G, Bethune D, Ridgway N, Xu Z. 2010. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2(1):48–51.
   PubMedGoogle Scholar
• Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, et al. 2020. Infectious Diseases Society of America guidelines on the treatment and management of  patients with COVID-19. Clin Infect Dis. ciaa478. DOI:10.1093/cid/ciaa478.
   Google Scholar
• Birdwell KA, Grady B, Choi L, Xu H, Bian A, Denny JC, Jiang M, Vranic G, Basford M, Cowan JD, et al. 2012. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics. 22(1):32–42.
   PubMed Web of Science ®Google Scholar
• Brackman DJ, Yee SW, Enogieru OJ, Shaffer C, Ranatunga D, Denny JC, Wei W-Q, Kamatani Y, Kubo M, Roden DM, et al. 2019. Genome-wide association and functional studies reveal novel pharmacological mechanisms for allopurinol. Clin Pharmacol Ther. 106(3):623–631.
   PubMed Web of Science ®Google Scholar
• Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC, Maciel A, Cullors A, Garces JA, Lukowiak AA. 2018. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 96:100–107.
   PubMed Web of Science ®Google Scholar
• Bråten LS, Haslemo T, Jukic MM, Ingelman-Sundberg M, Molden E, Kringen MK. 2020. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacol. 45(3):570–576.
   PubMed Web of Science ®Google Scholar
• Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J. 2016. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 19(3):213–228.
   PubMed Web of Science ®Google Scholar
• Buege MJ, DiPippo AJ, DiNardo CD. 2018. Evolving treatment strategies for elderly leukemia patients with IDH mutations. Cancers. 10(6):187.
   PubMed Web of Science ®Google Scholar
• Burt T, Dhillon S. 2013. Pharmacogenomics in early-phase clinical development. Pharmacogenomics. 14(9):1085–1097.
   PubMed Web of Science ®Google Scholar
• Caraballo PJ, Bielinski SJ, St Sauver JL, Weinshilboum RM. 2017. Electronic medical record-integrated pharmacogenomics and related clinical decision support concepts. Clin Pharmacol Ther. 102(2):254–264.
   PubMed Web of Science ®Google Scholar
• Carr DF, la Porte CJL, Pirmohamed M, Owen A, Cortes CP. 2010. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother. 65(9):1889–1893.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, et al. 2017. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 19(2):215–223.
   PubMed Web of Science ®Google Scholar
• Chair SY, Waye MMY, Calzone K, Chan CWH. 2019. Genomics education in nursing in Hong Kong, Taiwan and Mainland China. Int Nurs Rev. 66(4):459–466.
   PubMed Web of Science ®Google Scholar
• Chan HT, Chin YM, Low S-K. 2019. The roles of common variation and somatic mutation in cancer pharmacogenomics. Oncol Ther. 7(1):1–32.
   PubMed Web of Science ®Google Scholar
• Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. 2018. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol. 9:909.
   PubMed Web of Science ®Google Scholar
• Chiasson M, Dunham MJ, Rettie AE, Fowler DM. 2019. Applying multiplex assays to understand variation in pharmacogenes. Clin Pharmacol Ther. 106(2):290–294.
   PubMed Web of Science ®Google Scholar
• Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, Wu J-Y, Chen Y-T. 2004. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 428(6982):486–486.
   PubMed Web of Science ®Google Scholar
• Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. 2009. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 361(8):827–828.
   PubMed Web of Science ®Google Scholar
• Clarke JD, Cherrington NJ. 2012. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opin Drug Metab Toxicol. 8(3):349–360.
   PubMed Web of Science ®Google Scholar
• Collins T, Power K, McCallie D, Owings R. 2019. Finding a place for pharmacogenetics in the electronic health record. Clin Pharmacol Ther. 106(2):295–297.
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease. (COVID-19) Treatment guidelines. National Institute of Health (NIH). 2019. [Accessed 2021 Feb 1.]. https://www.covid19treatmentguidelines.nih.gov.
   Google Scholar
• Crisà E, Kulasekararaj AG, Adema V, Such E, Schanz J, Haase D, Shirneshan K, Best S, Mian SA, Kizilors A, et al. 2020. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia. 34(9):2441–2450.
   PubMed Web of Science ®Google Scholar
• da Cunha Santos G, Shepherd FA, Tsao M-S. 2011. EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69.
   PubMed Web of Science ®Google Scholar
• Daly AK. 2010. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 11(4):241–246.
   PubMed Web of Science ®Google Scholar
• Dang L, Yen K, Attar EC. 2016. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 27(4):599–608.
   PubMed Web of Science ®Google Scholar
• Davies EA, O'Mahony MS. 2015. Adverse drug reactions in special populations – the elderly. Br J Clin Pharmacol. 80(4):796–807.
   PubMed Web of Science ®Google Scholar
• Dehlin M, Jacobsson L, Roddy E. 2020. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 16(7):380–390.
   PubMed Web of Science ®Google Scholar
• Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, et al. 2018. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 24(7):1015–1023.
   PubMed Web of Science ®Google Scholar
• Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, et al. 2019. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. Clin Pharmacol Ther. 106(4):726–733.
   PubMed Web of Science ®Google Scholar
• Dewey FE, Murray MF, Overton JD, Habegger L, Leader JB, Fetterolf SN, O’Dushlaine C, Van Hout CV, Staples J, Gonzaga-Jauregui C, et al. 2016. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science. 354(6319):aaf6814.
   PubMed Web of Science ®Google Scholar
• Dhillon S. 2018. Ivosidenib: first global approval. Drugs. 78(14):1509–1516.
   PubMed Web of Science ®Google Scholar
• Dorr CR, Remmel RP, Muthusamy A, Fisher J, Moriarity BS, Yasuda K, Wu B, Guan W, Schuetz EG, Oetting WS, et al. 2017. CRISPR/Cas9 genetic modification of CYP3A5 *3 in HuH-7 human hepatocyte cell line leads to cell lines with increased midazolam and tacrolimus metabolism. Drug Metab Dispos. 45(8):957–965.
   PubMed Web of Science ®Google Scholar
• Dugger SA, Platt A, Goldstein DB. 2018. Drug development in the era of precision medicine. Nat Rev Drug Discov. 17(3):183–196.
   PubMed Web of Science ®Google Scholar
• Eid J, Fehr A, Gray J, Luong K, Lyle J, Otto G, Peluso P, Rank D, Baybayan P, Bettman B, et al. 2009. Real-time DNA sequencing from single polymerase molecules. Science. 323(5910):133–138.
   PubMed Web of Science ®Google Scholar
• Elliott LS, Henderson JC, Neradilek MB, Moyer NA, Ashcraft KC, Thirumaran RK. 2017. Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLOS One. 12(2):e0170905.
   PubMed Web of Science ®Google Scholar
• eMERGE Consortium. 2019. Harmonizing clinical sequencing and interpretation for the eMERGE III network. Am J Human Genet. 105:588–605.
   PubMed Web of Science ®Google Scholar
• FDA. Other FDA resources related to pharmacogenomics. 2021. [accessed 2021 Feb 20.] https://www.fda.gov/drugs/science-and-research-drugs/other-fda-resources-related-pharmacogenomics.
   Google Scholar
• FDA. Table of pharmacogenomic biomarkers in drug labeling. 2021. [accessed 2021 Feb 6] https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
   Google Scholar
• Feng Y, Zhang Y, Ying C, Wang D, Du C. 2015. Nanopore-based fourth-generation DNA sequencing technology. Genom Proteom Bioinform. 13(1):4–16.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al. 2015. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16(1):25–35.
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, et al. 2020. American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 72(6):744–760. 2020).
   PubMed Web of Science ®Google Scholar
• Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, VX 08-770-104 Study Group. 2012. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 142(3):718–724.
   PubMed Web of Science ®Google Scholar
• Fowler DM, Fields S. 2014. Deep mutational scanning: a new style of protein science. Nat Methods. 11(8):801–807.
   PubMed Web of Science ®Google Scholar
• Frick A, Benton CS, Scolaro KL, McLaughlin JE, Bradley CL, Suzuki OT, Wang N, Wiltshire T. 2016. Transitioning pharmacogenomics into the clinical setting: training future pharmacists. Front Pharmacol. 7:241.
   PubMed Web of Science ®Google Scholar
• Fujikura K, Ingelman-Sundberg M, Lauschke VM. 2015. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet Genom. 25(12):584–594.
   PubMed Web of Science ®Google Scholar
• Fukunaga K, Hishinuma E, Hiratsuka M, Kato K, Okusaka T, Saito T, Ikeda M, Yoshida T, Zembutsu H, Iwata N, et al. 2021. Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. J Hum Genet. 66(2):139–149.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. 2001. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 69(3):158–168.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. 2017. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 19(1):69–76.
   PubMed Web of Science ®Google Scholar
• Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. 2004. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 351(27):2827–2831.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Milia J, Cabarrou B, Bluthgen M-V, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, et al. 2015. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF cohort. J Thorac Oncol. 10(10):1451–1457.
   PubMed Web of Science ®Google Scholar
• Genin E, Chen D-P, Hung S-I, Sekula P, Schumacher M, Chang P-Y, Tsai S-H, Wu T-L, Bellón T, Tamouza R, et al. 2014. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 14(3):281–288.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. 2006. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355(26):2733–2743.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M. 2017. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov. 16(1):1–70.
   PubMed Web of Science ®Google Scholar
• Gordon AS, Fulton RS, Qin X, Mardis ER, Nickerson DA, Scherer S. 2016. PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet Genomics. 26(4):161–168.
   PubMed Web of Science ®Google Scholar
• Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, et al. 2019. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 111:59–67.
   PubMed Web of Science ®Google Scholar
• Gulilat M, Keller D, Linton B, Pananos AD, Lizotte D, Dresser GK, Alfonsi J, Tirona RG, Kim RB, Schwarz UI. 2020. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. J Thromb Thrombolysis. 49(2):294–303.
   PubMed Web of Science ®Google Scholar
• Gulilat M, Lamb T, Teft WA, Wang J, Dron JS, Robinson JF, Tirona RG, Hegele RA, Kim RB, Schwarz UI. 2019. Targeted next generation sequencing as a tool for precision medicine. BMC Med Genomics. 12(1):81–17.
   PubMed Web of Science ®Google Scholar
• Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, Dresser GK, Henderson SL, Rose RV, Lizotte DJ, et al. 2017. Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care. Can J Cardiol. 33(8):1036–1043.
   PubMed Web of Science ®Google Scholar
• Hachad H, Ramsey LB, Scott SA. 2019. Interpreting and implementing clinical pharmacogenetic tests: perspectives from service providers. Clin Pharmacol Ther. 106(2):298–301.
   PubMed Web of Science ®Google Scholar
• Han SM, Park J, Lee JH, Lee SS, Kim H, Han H, Kim Y, Yi S, Cho J-Y, Jang I-J, et al. 2017. Targeted next-generation sequencing for comprehensive genetic profiling of pharmacogenes. Clin Pharmacol Ther. 101(3):396–405.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. 2019. Breast cancer. Nat Rev Dis Primers. 5(1):66.
   PubMed Web of Science ®Google Scholar
• Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, et al. 2011. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 118(3):686–692.
   PubMed Web of Science ®Google Scholar
• Hauser AS, Chavali S, Masuho I, Jahn LJ, Martemyanov KA, Gloriam DE, Babu MM. 2018. Pharmacogenomics of GPCR drug targets. Cell. 172(1-2):41–54.e19.
   PubMed Web of Science ®Google Scholar
• Hiratsuka M. 2012. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet. 27(1):68–84
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NCP, Berger U, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16(11):2190–2196.
   PubMed Web of Science ®Google Scholar
• Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins R, On behalf of the HPS3/TIMI55–REVEAL Collaborative Group, et al. 2019. Impact of ADCY9 genotype on response to anacetrapib. Circulation. 140(11):891–898.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, et al. 2016. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• Huddart R, Sangkuhl K, Whirl-Carrillo M, Klein TE. 2019. Are randomized controlled trials necessary to establish the value of implementing pharmacogenomics in the clinic? Clin Pharmacol Ther. 106(2):284–286.
   PubMed Web of Science ®Google Scholar
• Hung S-I, Chung W-H, Liou L-B, Chu C-C, Lin M, Huang H-P, Lin Y-L, Lan J-L, Yang L-C, Hong H-S, et al. 2005. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci. 102(11):4134–4139.
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. 2016. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 176(12):1826–1833.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5(1):6–13.
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Iyer L, Xian Chen P, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, et al. 2004. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. JCO. 22(8):1382–1388
   PubMed Web of Science ®Google Scholar
• Ipe J, Swart M, Burgess KS, Skaar TC. 2017. High-throughput assays to assess the functional impact of genetic variants: a road towards genomic-driven medicine. Clin Transl Sci. 10(2):67–77.
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, monarchE Committee Members and Investigators, et al. 2020. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 38(34):3987–3998.]
   PubMed Web of Science ®Google Scholar
• Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M. 2018. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 Patients. Am J Psychiatry. 175(5):463–470/
   PubMed Web of Science ®Google Scholar
• Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, et al. 2016. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther. 99(2):172–185.
   PubMed Web of Science ®Google Scholar
• Kannangara DRW, Phipps-Green AJ, Dalbeth N, Stamp LK, Williams KM, Graham GG, Day RO, Merriman TR. 2016. Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Ann Rheum Dis. 75(7):1363–1366.
   PubMed Web of Science ®Google Scholar
• Kauppila M, Backman JT, Niemi M, Lapatto-Reiniluoto O. 2021. Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. Eur J Clin Pharmacol. 77(4):643–650.
   PubMed Web of Science ®Google Scholar
• Khunger A, Khunger M, Velcheti V. 2018. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis. 12:1753466618767611.
   Web of Science ®Google Scholar
• Kim RB. 2019. Precision medicine: lessons learned from implementation of a pharmacogenetics-based patient care program in a real-world setting. Clin Pharmacol Ther. 106(5):933–935.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Seeringer A, Godoy AL, Ohmle B, Maier C, Beschoner P, Sim E-J, Viviani R. 2011. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry. 16(3):333–341.
   Web of Science ®Google Scholar
• Klein K, Tremmel R, Winter S, Fehr S, Battke F, Scheurenbrand T, Schaeffeler E, Biskup S, Schwab M, Zanger UM. 2019. A new panel-based next-generation sequencing method for ADME genes reveals novel associations of common and rare variants with expression in a human liver cohort. Front Genet. 10:7.
   PubMed Web of Science ®Google Scholar
• Knepper TC, McLeod HL. 2018. When will clinical trials finally reflect diversity? Nature. 557(7704):157–159.
   PubMed Web of Science ®Google Scholar
• Koutsilieri S, Tzioufa F, Sismanoglou D-C, Patrinos GP. 2020. Towards harmonizing guidance for genome-informed drug treatment interventions: the show must go on. Pharmacol Res. 158:104839.
   PubMed Web of Science ®Google Scholar
• Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, et al. 2018. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nat Genet. 50(8):1081–1085.
   PubMed Web of Science ®Google Scholar
• Kozyra M, Ingelman-Sundberg M, Lauschke VM. 2017. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 19(1):20–29.
   PubMed Web of Science ®Google Scholar
• Krebs K, Bovijn J, Zheng N, Lepamets M, Censin JC, Jürgenson T, Särg D, Abner E, Laisk T, Luo Y, 23andMe Research Team, et al. 2020. Genome-wide Study identifies association between HLA-B∗55:01 and self-reported penicillin allergy. Am J Hum Genet. 107(4):612–621.
   PubMed Web of Science ®Google Scholar
• Kumar R, Mota LC, Litoff EJ, Rooney JP, Boswell WT, Courter E, Henderson CM, Hernandez JP, Corton JC, Moore DD, et al. 2017. Compensatory changes in CYP expression in three different toxicology mouse models: CAR-null, Cyp3a-null, and Cyp2b9/10/13-null mice. PLOS One. 12(3):e0174355.
   PubMed Web of Science ®Google Scholar
• Kuzelicki NK, et al. 2019. Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Pharmacogenomics. 20:643–657.
   PubMed Web of Science ®Google Scholar
• Lacaze P, Ronaldson KJ, Zhang EJ, Alfirevic A, Shah H, Newman L, Strahl M, Smith M, Bousman C, Francis B, et al. 2020. Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Transl Psychiatry. 10(1):37.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lamba V, Yasuda K, Lin YS, Assem M, Thompson E, Strom S, Schuetz E. 2004. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther. 311(2):811–821.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. 2016. Precision medicine and rare genetic variants. Trends Pharmacol Sci. 37(2):85–86.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. 2016. Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics. 17(8):917–924.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. 2016. The importance of patient-specific factors for hepatic drug response and toxicity. IJMS. 17(10):1714.
   Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. 2018. How to consider rare genetic variants in personalized drug therapy. Clin Pharmacol Ther. 103(5):745–748.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. 2019. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 130:65–77.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Ingelman-Sundberg M. 2020. Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ Genom Med. 5:9.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Milani L, Ingelman-Sundberg M. 2017. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. AAPS J. 20(1):4.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Zhou Y, Ingelman-Sundberg M. 2019. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 197:122–152.
   PubMed Web of Science ®Google Scholar
• Lee AM, et al. 2014. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Instit. 106:dju298.
   PubMedGoogle Scholar
• Leucht S, Helfer B, Gartlehner G, Davis JM. 2015. How effective are common medications: a perspective based on meta-analyses of major drugs. BMC Med. 13:253.
   PubMed Web of Science ®Google Scholar
• Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, Xie Y, Peng L, Xu X, Li J, et al. 2018. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. PLOS One. 13(9):e0203495.
   PubMed Web of Science ®Google Scholar
• Liau Y, Maggo S, Miller AL, Pearson JF, Kennedy MA, Cree SL. 2019. Nanopore sequencing of the pharmacogene CYP2D6 allows simultaneous haplotyping and detection of duplications. Pharmacogenomics. 20(14):1033–1047.
   PubMed Web of Science ®Google Scholar
• Limdi NA, Goldstein JA, Blaisdell JA, Beasley TM, Rivers CA, Acton RT. 2007. Influence of CYP2C9 genotype on warfarin dose among African American and European Americans. Personal Med. 4(2):157–169.
   PubMed Web of Science ®Google Scholar
• Linderman MD, Sanderson SC, Bashir A, Diaz GA, Kasarskis A, Zinberg R, Mahajan M, Suckiel SA, Zweig M, Schadt EE. 2018. Impacts of incorporating personal genome sequencing into graduate genomics education: a longitudinal study over three course years. BMC Med Genomics. 11(1):5.
   PubMed Web of Science ®Google Scholar
• List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2021. FDA. [accessed 2021 Mar 7.] https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools.
   Google Scholar
• Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, et al. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 358(6):568–579.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, et al. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci. 101(12):4180–4185.
   PubMed Web of Science ®Google Scholar
• Martincorena I, Campbell PJ. 2015. Somatic mutation in cancer and normal cells. Science. 349(6255):1483–1489.
   PubMed Web of Science ®Google Scholar
• McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PIW, et al. 2011. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 364(12):1134–1143.
   PubMed Web of Science ®Google Scholar
• Medwid S, Li MMJ, Knauer MJ, Lin K, Mansell SE, Schmerk CL, Zhu C, Griffin KE, Yousif MD, Dresser GK, et al. 2019. Fexofenadine and rosuvastatin pharmacokinetics in mice with targeted disruption of organic anion transporting polypeptide 2B1. Drug Metab Dispos. 47(8):832–842.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, et al. 2015. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16(16):1639–1650.
   PubMed Web of Science ®Google Scholar
• Meyer zu Schwabedissen HE, Oswald S, Bresser C, Nassif A, Modess C, Desta Z, Ogburn ET, Marinova M, Lütjohann D, Spielhagen C, et al. 2012. Compartment-specific gene regulation of the CAR inducer efavirenz in vivo. Clin Pharmacol Ther. 92(1):103–111.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WSME, et al. 2017. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Mondesir J, Willekens C, Touat M, de Botton S. 2016. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 7:171–180.
   PubMed Web of Science ®Google Scholar
• Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, Roden DM. 2013. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 23(8):383–394.
   PubMed Web of Science ®Google Scholar
• Need AC, Goldstein DB. 2009. Next generation disparities in human genomics: concerns and remedies. Trends Genet. 25(11):489–494.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, Shen J, Tang Z, Bacanu S-A, Fraser D, et al. 2012. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 337(6090):100–104.
   PubMed Web of Science ®Google Scholar
• Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel K-D, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, et al. 2010. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 88(5):676–684.
   PubMed Web of Science ®Google Scholar
• Nguyen CM, Mendes MAS, Ma JD. 2011. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLOS Curr. 3:RRN1236.
   PubMedGoogle Scholar
• Nicolas E, Bertucci F, Sabatier R, Gonçalves A. 2018. Targeting BRCA deficiency in breast cancer: what are the clinical evidences and the next perspectives? Cancers. 10(12):506.
   PubMed Web of Science ®Google Scholar
• Norgeot B, Glicksberg BS, Butte AJ. 2019. A call for deep-learning healthcare. Nat Med. 25(1):14–15.
   PubMed Web of Science ®Google Scholar
• Norgeot B, Muenzen K, Peterson TA, Fan X, Glicksberg BS, Schenk G, Rutenberg E, Oskotsky B, Sirota M, Yazdany J, et al. 2020. Protected Health Information filter (Philter): accurately and securely de-identifying free-text clinical notes. NPJ Digit Med. 3:57–58.
   PubMed Web of Science ®Google Scholar
• Onishi-Seebacher M, Korbel JO. 2011. Challenges in studying genomic structural variant formation mechanisms: the short-read dilemma and beyond. Bioessays. 33(11):840–850.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. 2006. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genom. 16(12):873–879.
   PubMed Web of Science ®Google Scholar
• Patrinos GP, Mitropoulou C. 2017. Measuring the value of pharmacogenomics evidence. Clin Pharmacol Ther. 15:349–343.
   Google Scholar
• Pereira B, Chin S-F, Rueda OM, Vollan H-KM, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut S-J, et al. 2016. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 7:11479.
   PubMed Web of Science ®Google Scholar
• Pérez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Sáez-Navarro C, Bobes J, Baca-García E, Vieta E, Olivares JM, AB-GEN Collaborative Group, et al. 2017. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 17(1):250.
   PubMed Web of Science ®Google Scholar
• Peterson TA, Doughty E, Kann MG. 2013. Towards precision medicine: advances in computational approaches for the analysis of human variants. J Mol Biol. 425(21):4047–4063.
   PubMed Web of Science ®Google Scholar
• Pikor LA, Ramnarine VR, Lam S, Lam WL. 2013. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 82(2):179–189.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, et al. 2013. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 369(24):2294–2303.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Hughes DA. 2013. Pharmacogenetic tests: the need for a level playing field. Nat Rev Drug Discov. 12(1):3–4.
   PubMed Web of Science ®Google Scholar
• Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM, Zhang P, Mookerjee B, et al. 2017. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 18(10):1307–1316.
   PubMed Web of Science ®Google Scholar
• Pritchard DE, Moeckel F, Villa MS, Housman LT, McCarty CA, McLeod HL. 2017. Strategies for integrating personalized medicine into healthcare practice. Per Med. 14(2):141–152.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Nichols KE, Yang JJ. 2019. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol. 16(4):227–240.
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Brenner H. 2020. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 10(5):56.
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. 2011. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 365(18):1663–1672.
   PubMed Web of Science ®Google Scholar
• Rautureau Y, Deschambault V, Higgins M-È, Rivas D, Mecteau M, Geoffroy P, Miquel G, Uy K, Sanchez R, Lavoie V, et al. 2018. ADCY9 (Adenylate Cyclase Type 9) inactivation protects from atherosclerosis only in the absence of CETP(Cholesteryl Ester Transfer Protein). Circulation. 138(16):1677–1692.
   PubMed Web of Science ®Google Scholar
• Relling MV, Evans WE. 2015. Pharmacogenomics in the clinic. Nature. 526(7573):343–350.
   PubMed Web of Science ®Google Scholar
• Rodrigues D, Rowland A. 2019. From endogenous compounds as biomarkers to plasma-derived nanovesicles as liquid biopsy; has the golden age of translational pharmacokinetics-absorption, distribution, metabolism, excretion-drug-drug interaction science finally arrived? Clin Pharmacol Ther. 105(6):1407–1420.
   PubMed Web of Science ®Google Scholar
• Rossari F, Minutolo F, Orciuolo E. 2018. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 11(1):84.
   PubMed Web of Science ®Google Scholar
• Rowland A, Ruanglertboon W, van Dyk M, Wijayakumara D, Wood LS, Meech R, Mackenzie PI, Rodrigues AD, Marshall J-C, Sorich MJ. 2019. Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure. Br J Clin Pharmacol. 85(1):216–226.
   PubMed Web of Science ®Google Scholar
• Russell LE, DeGorter MK, Ho RH, Leake BF, Schmerk CL, Mansell SE, Kim RB. 2021. Mouse NTCP-mediated rosuvastatin uptake in vitro and in Slc10a1-deficient mice. AAPS J. 23(1):17.
   PubMed Web of Science ®Google Scholar
• Russell LE, Schwarz UI. 2020. Variant discovery using next-generation sequencing and its future role in pharmacogenetics. Pharmacogenomics. 21(7):471–486.
   PubMed Web of Science ®Google Scholar
• Russell LE, Zhou Y, Lauschke VM, Kim RB. 2020. In vitro functional characterization and in silico prediction of rare genetic variation in the bile acid and drug transporter, Na+-taurocholate cotransporting polypeptide (NTCP, SLC10A1. Mol Pharmaceutics. 17(4):1170–1181.
   PubMed Web of Science ®Google Scholar
• Sabir SR, Yeoh S, Jackson G, Bayliss R. 2017. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers. 9:1–9.
   Web of Science ®Google Scholar
• Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, PANTS Consortium, et al. 2020. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology. 158(1):189–199.
   PubMed Web of Science ®Google Scholar
• Schaller L, Lauschke VM. 2019. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum Genet. 138(11–12):1359–1377.
   PubMed Web of Science ®Google Scholar
• Schärfe CPI, Tremmel R, Schwab M, Kohlbacher O, Marks DS. 2017. Genetic variation in human drug-related genes. Genome Med. 9(1):117–115.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. 2018. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 367(22):2089–2099.
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, Mizuguchi K, Ho RH, Kim RB. 2011. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics. 21(3):103–114.
   PubMed Web of Science ®Google Scholar
• Schwarze K, Buchanan J, Taylor JC, Wordsworth S. 2018. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 20(10):1122–1130.
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. 2008. SLCO1B1 variants and statin-induced myopathy–a genomewide study. New Eng J Med. 359:789–799.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. 2019. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 36:70–87.
   PubMed Web of Science ®Google Scholar
• Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M. 2020. Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements. Clin Pharmacol Ther. 107(5):1240–1255.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR. 2009. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 302(8):849–857.
   PubMed Web of Science ®Google Scholar
• Sim SC, Kacevska M, Ingelman-Sundberg M. 2013. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 13(1):1–11.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Liu S, Benet LZ. 2020. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition. Pharm Res. 37(10):208–213.
   PubMed Web of Science ®Google Scholar
• Spear BB, Heath-Chiozzi M, Huff J. 2001. Clinical application of pharmacogenetics. Trends Mol Med. 7(5):201–204.
   PubMed Web of Science ®Google Scholar
• Spring LM, Wander SA, Zangardi M, Bardia A. 2019. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep. 21(3):25.
   PubMed Web of Science ®Google Scholar
• St Sauver JL, Bielinski SJ, Olson JE, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Caraballo PJ, Takahashi PY, Roger VL, et al. 2016. Integrating pharmacogenomics into clinical practice: promise vs reality. Am J Med. 129(10):1093–1099.
   PubMed Web of Science ®Google Scholar
• Suiter CC, Moriyama T, Matreyek KA, Yang W, Scaletti ER, Nishii R, Yang W, Hoshitsuki K, Singh M, Trehan A, et al. 2020. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci USA. 117(10):5394–5401.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Luzum JA, Nicol MR, Jacobson PA. 2020. Pharmacogenomics of COVID-19 therapies. NPJ Genom Med. 5:35.
   PubMed Web of Science ®Google Scholar
• Takechi T, Hirota T, Sakai T, Maeda N, Kobayashi D, Ieiri I. 2018. Interindividual differences in the expression of ATP-binding cassette and solute carrier family transporters in human skin: DNA methylation regulates transcriptional activity of the human ABCC3 gene. Drug Metab Dispos. 46(5):628–635.
   PubMed Web of Science ®Google Scholar
• Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al. 2009. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLOS Genet. 5(3):e1000433-1000439.
   Web of Science ®Google Scholar
• Tardif J-C, Rhéaume E, Lemieux Perreault L-P, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L’Allier PL, et al. 2015. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 8(2):372–382.
   PubMed Web of Science ®Google Scholar
• Tasa T, Krebs K, Kals M, Mägi R, Lauschke VM, Haller T, Puurand T, Remm M, Esko T, Metspalu A, et al. 2019. Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records. Eur J Hum Genet. 27(3):442–454.
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. 2004. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 104(12):3739–3745.
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Droll KP, Sellers EM. 1997. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 7:375–379.
   PubMedGoogle Scholar
• Tzvetkov MV. 2017. OCT1 pharmacogenetics in pain management: is a clinical application within reach? Pharmacogenomics. 18(16):1515–1523.
   PubMed Web of Science ®Google Scholar
• Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, Tabuchi Y, Ozawa T, Itoh H, Horie M, et al. 2017. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genom. 27(9):329–336.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Wagenaar E, van der Kruijssen CMM, Burggraaff JEC, de Waart DR, Elferink RPJO, Kenworthy KE, Schinkel AH. 2010. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest. 120(8):2942–2952.
   PubMed Web of Science ®Google Scholar
• van der Baan FH, Klungel OH, Egberts ACG, Leufkens HG, Grobbee DE, Roes KCB, Knol MJ. 2011. Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics. 12(10):1485–1492.
   PubMed Web of Science ®Google Scholar
• van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Ubiquitous Pharmacogenomics Consortium, et al. 2017. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 101(3):341–358.
   PubMed Web of Science ®Google Scholar
• van Dijk EL, Jaszczyszyn Y, Naquin D, Thermes C. 2018. The third revolution in sequencing technology. Trends Genet. 34(9):666–681.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Wells QS, Stallings S, Bush WS, Gordon A, Nickerson DA, Kim JH, Crosslin DR, Jarvik GP, Carrell DS, et al. 2016. Association of arrhythmia-related genetic variants with phenotypes documented in electronic medical records. JAMA. 315(1):47–57.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. 2011. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 108(46):18843–18848.
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. 2009. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 106:18825–18830.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB, et al. 2000. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 6:4705–4712.
   PubMed Web of Science ®Google Scholar
• Verbelen M, Weale ME, Lewis CM. 2017. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 17(5):395–402.
   PubMed Web of Science ®Google Scholar
• Vest BM, Wray LO, Brady LA, Thase ME, Beehler GP, Chapman SR, Hull LE, Oslin DW. 2020. Primary care and mental health providers' perceptions of implementation of pharmacogenetics testing for depression prescribing. BMC Psychiatry. 20(1):518.
   PubMed Web of Science ®Google Scholar
• Viviani R, Messina I, Bosch JE, Dommes L, Paul A, Schneider KL, Scholl C, Stingl JC. 2020. Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity. Transl Psychiatry. 10(1):338–339.
   PubMed Web of Science ®Google Scholar
• Wagner JB, Abdel-Rahman S, Van Haandel L, Gaedigk A, Gaedigk R, Raghuveer G, Kauffman R, Leeder JS. 2018. Impact of SLCO1B1 genotype on pediatric simvastatin acid pharmacokinetics. J Clin Pharmacol. 58(6):823–833.
   PubMed Web of Science ®Google Scholar
• Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE. 2016. Educational strategies to enable expansion of pharmacogenomics-based care. Am J Health Syst Pharm. 73(23):1986–1998.
   PubMed Web of Science ®Google Scholar
• Wen CC, Yee SW, Liang X, Hoffmann TJ, Kvale MN, Banda Y, Jorgenson E, Schaefer C, Risch N, Giacomini KM. 2015. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 97(5):518–525.
   PubMed Web of Science ®Google Scholar
• Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G. 2011. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther. 89(3):379–386.
   PubMed Web of Science ®Google Scholar
• Wouden CH, van Rhenen MH, Jama WOM, Ingelman‐Sundberg M, Lauschke VM, Konta L, Schwab M, Swen JJ, Guchelaar H‐J. 2019. Development of the PGx-passport: a panel of actionable germline genetic variants for pre-emptive pharmacogenetic testing. Clin Pharmacol Ther. 106(4):866–873.
   PubMed Web of Science ®Google Scholar
• Wrenbeck EE, Klesmith JR, Stapleton JA, Adeniran A, Tyo KEJ, Whitehead TA. 2016. Plasmid-based one-pot saturation mutagenesis. Nat Methods. 13(11):928–930.
   PubMed Web of Science ®Google Scholar
• Wright GEB, Carleton B, Hayden MR, Ross CJD. 2018. The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics J. 18(1):187–195.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhou Y, Lauschke VM. 2020. Ethnogeographic and inter-individual variability of human ABC transporters. Hum Genet. 139(5):623–646.
   PubMed Web of Science ®Google Scholar
• Xu Z-q, Zhang Y, Li N, Liu P-j, Gao L, Gao X, Tie X-j. 2017. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 7(3):e013053.
   PubMed Web of Science ®Google Scholar
• Yan C, Pattabiraman N, Goecks J, Lam P, Nayak A, Pan Y, Torcivia-Rodriguez J, Voskanian A, Wan Q, Mazumder R. 2017. Impact of germline and somatic missense variations on drug binding sites. Pharmacogenomics J. 17(2):128–136.
   PubMed Web of Science ®Google Scholar
• Young J, Bhattacharya K, Ramachandran S, Lee A, Bentley JP. 2021. Rates of genetic testing in patients prescribed drugs with pharmacogenomic information in FDA-approved labeling. The Pharmacogenomics Journal. 319:2379–2378.
   Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zhang B, Lauschke VM. 2019. Genetic variability and population diversity of the human SLCO (OATP) transporter family. Pharmacol Res. 139:550–559.
   PubMed Web of Science ®Google Scholar
• Zhang L, Sarangi V, Moon I, Yu J, Liu D, Devarajan S, Reid JM, Kalari KR, Wang L, Weinshilboum R. 2020. CYP2C9 and CYP2C19: deep mutational scanning and functional characterization of genomic missense variants. Clin Transl Sci. 13(4):727–742.
   PubMed Web of Science ®Google Scholar
• Zheng LY, Rifkin BR, Spielman AI, London L, London SD. 2019. The Teaching of personalized dentistry in North American dental schools: changes from 2014 to 2017. J Dent Educ. 83(9):1065–1075.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Dagli Hernandez C, Lauschke VM. 2020. Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. Br J Cancer. 123(12):1782–1789.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fujikura K, Mkrtchian S, Lauschke VM. 2018. Computational methods for the pharmacogenetic interpretation of next generation sequencing data. Front Pharmacol. 9:1437.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Herras Arribas G, Turku A, Jürgenson T, Mkrtchian S, Krebs K, Wang Y, Svobodova B, Milani L, Schulte G, et al. Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine. Sci Adv. (Under consideration).
   Google Scholar
• Zhou Y, Ingelman-Sundberg M, Lauschke VM. 2017. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 102(4):688–700.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Krebs K, Milani L, Lauschke VM. 2021. Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 109(1):160–174.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM. 2019. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. 19(2):115–126.
   PubMed Web of Science ®Google Scholar